Sun Pharma’s Utreglutide Shows Promising Weight Loss and Metabolic Benefits in Obesity and MASLD Studies

Sun Pharmaceutical Industries Limited has unveiled encouraging results from clinical studies evaluating GL0034 (Utreglutide), a once-weekly GLP-1 receptor agonist targeting obesity and MASLD. In a 10-week dosing regimen, participants experienced a clinically meaningful average body weight reduction of 6.8%. Extended data from a 13-week trial in obesity and MASLD patients also showed substantial improvements in liver fat, fibrosis markers, glucose metabolism, lipid profiles, and inflammation biomarkers.

 

These findings underscore GL0034’s potential not only to induce weight loss but also to improve associated cardio-metabolic health parameters, including reductions in HbA1c, triglycerides, total cholesterol, and non-HDL cholesterol. The studies reported favorable tolerability, with gastrointestinal side effects consistent with this drug class.

 

Sun Pharma’s lead investigator, Dr. Rajamannar Thennati, highlighted the compound’s novel ability to simultaneously address obesity and related metabolic liver disease, positioning GL0034 as a promising therapeutic advance warranting further large-scale clinical trials.

 

Key Highlights:

Source: Sun Pharma, Diabetes Journals, Medical Dialogues, Clinical Trials Arena